| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
CBT Stock Overview
Cabot Corporation operates as a specialty chemicals and performance materials company.
Cabot Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.08 |
| 52 Week High | US$65.25 |
| 52 Week Low | US$42.72 |
| Beta | 1.64 |
| 1 Month Change | 11.89% |
| 3 Month Change | 7.98% |
| 1 Year Change | 21.35% |
| 3 Year Change | 28.33% |
| 5 Year Change | 3.24% |
| Change since IPO | 532.16% |
Recent News & Updates
Under The Bonnet, Cabot's (NYSE:CBT) Returns Look Impressive
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...
Cabot: A Few Interesting Developments
CBT’s decision to sell its Purification Solutions division should be taken well. CBT’s Investor Day to be held later this week may prove to be a positive trigger. The stock is well-placed relative to other material stocks and also appears to be cheap relative to its average forward multiples.
When Should You Buy Cabot Corporation (NYSE:CBT)?
While Cabot Corporation ( NYSE:CBT ) might not be the most widely known stock at the moment, it saw a decent share...
Shareholder Returns
| CBT | US Chemicals | US Market | |
|---|---|---|---|
| 7D | -1.3% | -3.5% | -4.6% |
| 1Y | 21.4% | 12.0% | 7.7% |
Return vs Industry: CBT exceeded the US Chemicals industry which returned 13% over the past year.
Return vs Market: CBT exceeded the US Market which returned 10.2% over the past year.
Price Volatility
| CBT volatility | |
|---|---|
| CBT Average Weekly Movement | 4.3% |
| Chemicals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: CBT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CBT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1882 | 4,500 | Sean Keohane | https://www.cabotcorp.com |
Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through three segments: Reinforcement Materials, Performance Chemicals, and Purification Solutions. The company offers reinforcing carbons used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites.
Cabot Fundamentals Summary
| CBT fundamental statistics | |
|---|---|
| Market Cap | US$3.30b |
| Earnings (TTM) | US$247.00m |
| Revenue (TTM) | US$3.41b |
13.4x
P/E Ratio1.0x
P/S RatioIs CBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBT income statement (TTM) | |
|---|---|
| Revenue | US$3.41b |
| Cost of Revenue | US$2.60b |
| Gross Profit | US$806.00m |
| Expenses | US$559.00m |
| Earnings | US$247.00m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Jan 31, 2022
| Earnings per share (EPS) | 4.35 |
| Gross Margin | 23.64% |
| Net Profit Margin | 7.25% |
| Debt/Equity Ratio | 103.6% |
How did CBT perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield32%
Payout RatioDoes CBT pay a reliable dividends?
See CBT dividend history and benchmarks| Cabot dividend dates | |
|---|---|
| Ex Dividend Date | Feb 24 2022 |
| Dividend Pay Date | Mar 11 2022 |
| Days until Ex dividend | 35 days |
| Days until Dividend pay date | 50 days |
Does CBT pay a reliable dividends?
See CBT dividend history and benchmarksValuation
Is Cabot undervalued compared to its fair value and its price relative to the market?
13.36x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CBT ($58.08) is trading above our estimate of fair value ($51.74)
Significantly Below Fair Value: CBT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CBT is good value based on its PE Ratio (13.4x) compared to the US Chemicals industry average (21.6x).
PE vs Market: CBT is good value based on its PE Ratio (13.4x) compared to the US market (17x).
Price to Earnings Growth Ratio
PEG Ratio: CBT is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: CBT is overvalued based on its PB Ratio (3.5x) compared to the US Chemicals industry average (2.5x).
Future Growth
How is Cabot forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
15.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CBT's forecast earnings growth (15.4% per year) is above the savings rate (2%).
Earnings vs Market: CBT's earnings (15.4% per year) are forecast to grow faster than the US market (13% per year).
High Growth Earnings: CBT's earnings are forecast to grow, but not significantly.
Revenue vs Market: CBT's revenue (4.5% per year) is forecast to grow slower than the US market (9.2% per year).
High Growth Revenue: CBT's revenue (4.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CBT's Return on Equity is forecast to be very high in 3 years time (48.3%).
Past Performance
How has Cabot performed over the past 5 years?
-24.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CBT has high quality earnings.
Growing Profit Margin: CBT became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CBT's earnings have declined by 24.6% per year over the past 5 years.
Accelerating Growth: CBT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CBT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (17.5%).
Return on Equity
High ROE: Whilst CBT's Return on Equity (26.24%) is high, this metric is skewed due to their high level of debt.
Financial Health
How is Cabot's financial position?
Financial Position Analysis
Short Term Liabilities: CBT's short term assets ($1.4B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: CBT's short term assets ($1.4B) exceed its long term liabilities ($1.1B).
Debt to Equity History and Analysis
Debt Level: CBT's net debt to equity ratio (88.2%) is considered high.
Reducing Debt: CBT's debt to equity ratio has increased from 69.1% to 103.6% over the past 5 years.
Debt Coverage: CBT's debt is well covered by operating cash flow (22.8%).
Interest Coverage: CBT's interest payments on its debt are well covered by EBIT (12.1x coverage).
Balance Sheet
Dividend
What is Cabot current dividend yield, its reliability and sustainability?
2.55%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: CBT's dividend (2.55%) is higher than the bottom 25% of dividend payers in the US market (1.35%).
High Dividend: CBT's dividend (2.55%) is low compared to the top 25% of dividend payers in the US market (3.48%).
Stability and Growth of Payments
Stable Dividend: CBT's dividends per share have been stable in the past 10 years.
Growing Dividend: CBT's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (32.1%), CBT's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: CBT's dividends in 3 years are forecast to be well covered by earnings (26.3% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.6yrs
Average management tenure
CEO
Sean Keohane (54 yo)
5.83yrs
Tenure
US$5,817,523
Compensation
Mr. Sean D. Keohane serves as Independent Director of The Chemours Companysince May 3, 2018. He has been the Chief Executive Officer and President of Cabot Corporation since March 11, 2016. He was a member...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD5.82M) is about average for companies of similar size in the US market ($USD5.14M).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: CBT's management team is considered experienced (4.6 years average tenure).
Board Members
Experienced Board: CBT's board of directors are considered experienced (5.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Cabot Corporation's employee growth, exchange listings and data sources
Key Information
- Name: Cabot Corporation
- Ticker: CBT
- Exchange: NYSE
- Founded: 1882
- Industry: Commodity Chemicals
- Sector: Materials
- Implied Market Cap: US$3.299b
- Shares outstanding: 56.80m
- Website: https://www.cabotcorp.com
Number of Employees
Location
- Cabot Corporation
- Two Seaport Lane
- Suite 1400
- Boston
- Massachusetts
- 02210-2019
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/19 23:32 |
| End of Day Share Price | 2022/01/19 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2021/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.